Todd Tushla | executive |
Kevin Gorman | executive |
Matthew Abernethy | executive |
Eric Benevich | executive |
Eiry Roberts | executive |
Philip Nadeau | analyst |
Paul Matteis | analyst |
Tazeen Ahmad | analyst |
Anupam Rama | analyst |
Akash Tewari | analyst |
Jay Olson | analyst |
Kyle Gano | executive |
Kevin Strang | analyst |
Brian Skorney | analyst |
Mohit Bansal | analyst |
Marc Goodman | analyst |
Carter L. Gould | analyst |
Myles Minter | analyst |
Johoon Kim | analyst |
Cory Kasimov | analyst |
Laura Chico | analyst |
Good day, everyone, and welcome to today's Neurocrine Biosciences Reports Second Quarter Results. [Operator Instructions] Please note today's call will be recorded [Operator Instructions] It is now my pleasure to turn the conference over to Vice President of Investor Relations, Todd Tushla. Please go ahead.
Thank you, Chloe. Welcome to Neurocrine Biosciences Second Quarter 2024 Earnings Call.